Sumitomo Pharma Co.ltd. (4506) Press Release
Matters Concerning Controlling Shareholders, Etc.
Earlier from Sumitomo Pharma Co.ltd
- Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
- Sumitomo Pharma: Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change
- New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
- Sumitomo Pharma: May 13, 2026 Conference on FY2025 Financial Results transcript（PDF/5,711KB）